JNJ vs ZBH: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
JNJ is the larger of the two ($617.78B market cap): the incumbent the market prices for continued execution (20.07x forward earnings, beta 0.23). ZBH is the smaller challenger ($18.97B), cheaper on forward earnings (10.97x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
JNJ vs ZBH: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | JNJ | ZBH | What it tells you |
|---|---|---|---|
| Market cap | $617.78B | $18.97B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 20.07 | 10.97 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 29.77 | 24.15 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.23 | 0.46 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 83% of range | 73% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 7.27 | 1.50 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ZBH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how JNJ and ZBH affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and ZBH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and ZBH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Johnson & Johnson (JNJ) do?
Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.
What does Zimmer Biomet (ZBH) do?
Zimmer Biomet Holdings, based in Warsaw, Indiana, makes the hardware that goes inside roughly a million joint replacement patients a year. Its reporting lines are knees, hips, S.E.T. (sports medicine, extremities and trauma), and craniomaxillofacial and thoracic, with a separate technology and data line covering the ROSA robotic platform, navigation and mixed-reality software. Trailing twelve-month revenue runs about ~$8.51B across roughly 17,000 employees. Two acquisitions reshaped the mix recently: Paragon 28 for about ~$1.2B, which added a dedicated foot and ankle franchise, and Monogram Technologies for about ~$177M in equity value (~$4.04 per share, closed in 2025), which brought semi-autonomous and autonomous robotic capability alongside the existing ROSA installed base of nearly 2,000 systems.
JNJ vs ZBH: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
- ZBH drivers: Hips and technology are carrying the growth, not knees; ROSA is a placement business, not a robot business.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For ZBH, the most concrete overhang is credibility: the November 5, 2025 guidance pivot cut the price roughly 15% in a day, and in January 2026 Hagens Berman announced an investigation into whether management misled investors about international stability (as of August 2026 that remains an investigation notice, with no securities complaint on file).
JNJ or ZBH: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JNJ if you believe its drivers more; ZBH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and ZBH guides.
JNJ vs ZBH: the full fundamentals
JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.
ZBH. At a market capitalization near ~$18.97B, Zimmer Biomet is valued at roughly 2.2x trailing sales and about ~11x to ~12x guided 2026 adjusted earnings. Stryker trades near ~20.6x forward earnings and Johnson & Johnson near ~23.5x, so the gap is not marginal, it is close to half. What the multiple is arguing about is durability of growth rather than current profitability: adjusted operating margin near ~25.7% is still healthy, but it is heading down this year while the reported organic growth rate sits in the low single digits.
Headline figures (approximate, early 2026): JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x; ZBH shows revenue (ttm) ~$8.51B, q2 2026 net sales ~$2.18B, up ~4.8% reported and ~4% organic constant currency, 2026 adjusted eps guidance ~$8.47 to ~$8.59 (raised), forward p/e ~11.7x guidance midpoint at ~$99 per share.
The bottom line: JNJ vs ZBH
JNJ and ZBH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JNJ and ZBH exposure against your real portfolio. It is not an investment adviser.
Wondering how JNJ or ZBH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Johnson & Johnson with AI
Connect the broker you already use and ask Walnut's AI how JNJ fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between JNJ and ZBH?
+
Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Zimmer Biomet Holdings, based in Warsaw, Indiana, makes the hardware that goes inside roughly a million joint replacement patients a year. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is JNJ or ZBH the better stock?
+
Neither is universally better. JNJ is the larger incumbent; ZBH is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, JNJ or ZBH?
+
On forward P/E (as of August 2026), JNJ trades at 20.07x and ZBH at 10.97x, so ZBH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both JNJ and ZBH?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of JNJ vs ZBH?
+
JNJ: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. Drug pricing pressure, including US government negotiation of certain drug prices, can weigh on margins. The company also faces significant legal liability, most notably ongoing litigation related to talc-based products, which has created uncertainty and large potential settlements. MedTech competes in tough device markets and is exposed to hospital budgets and procedure volumes. Regulatory, clinical-trial, and product-safety risks are inherent to healthcare. Growth is steady rather than rapid, so J&J is valued as a defensive compounder rather than a high-growth name. ZBH: The most concrete overhang is credibility: the November 5, 2025 guidance pivot cut the price roughly 15% in a day, and in January 2026 Hagens Berman announced an investigation into whether management misled investors about international stability (as of August 2026 that remains an investigation notice, with no securities complaint on file). Margin direction is the second issue, since adjusted operating margin fell ~210 basis points year over year to ~25.7% and the company itself guides to a slight full-year decline. China is small at roughly 2% of revenue and 1% of EBITDA but was down about 20% this year under volume-based procurement tenders, and VBP-style pricing pressure has a habit of spreading to other categories. Tariffs cut both ways here: a favorable ~$30M adjustment for probable US refunds helped first-half 2026 profit and does not repeat, and the company's largely domestic manufacturing base limits but does not eliminate exposure. Longer term, competitive pressure from Stryker's Mako franchise and the unresolved argument over whether GLP-1 weight-loss drugs shrink or expand the eligible joint replacement population both sit outside management's control.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell JNJ or ZBH; figures are approximate and dated (as of August 2026). Verify current data before investing.